Schiweck Weinzierl Koch Patentanwälte Partnerschaft mbB

The present invention provides peptides useful as epitope tags, which may be fused to a polypeptide of interest, as well as antibodies that specifically bind to these peptides. The peptides and/or antibodies can be used for detecting, immobilizing, isolating or purifying a molecule that is conjugated to such a peptide and/or antibody.

Provided are a potentiometric biosensor (100) and a method for detecting urea concentration in a sample. The potentiometric biosensor (100) comprises an indication electrode (23) and a reference electrode (24). A second reaction reagent on the indication electrode (23) comprises a urease but does not comprise an electron transporter. A first reaction reagent on the reference electrode (24) comprises an electron transporter but does not comprise a urease. In the case where no external voltage is applied, after a blood sample has been added, the urease catalyzes the reaction of urea in the sample, thereby causing a potential difference between the indication electrode (23) and the reference electrode (24). Furthermore, the potential difference between the indication electrode (23) and the reference electrode (24) is in a linear relationship with the urea concentration in the sample, and the urea concentration in the sample can be calculated according to such linear relationship.

Disclosed herein are methods and compositions for detecting one or more pathogens that cause atypical pneumonia. Detectable pathogens include Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.

The present application relates to the field of sequencing image data processing technology, and in particular, to a method for detecting an abnormal region in an image, a method for base calling by processing an abnormal region in an image, and a related device. In the present application, the abnormal region is identified by analyzing the intensity of the pixel where the position of the nucleic acid template is located in the image of interest and the brightness of image blocks in the image of interest, and the intensity of the position of the nucleic acid template in the abnormal region is zeroed, so as to identify the base type of the nucleic acid template incorporated into the abnormal region in the sequencing process as unknown, thereby eliminating the abnormal signal interference and improving the accuracy of base sequencing.

The present invention relates to a bispecific antibody construct for use in treating non-small cell lung cancer (NSCLC) in a subject, optionally in combination with an immune checkpoint inhibitor, wherein the bispecific antibody construct is administered in a loading dose for a first period of time, and is then administered in a maintenance dose for a second period of time, wherein the loading dose is higher than the maintenance dose. Also provided are compositions comprising an immune checkpoint inhibitor and a bispecific antibody construct and there use in treating non-small cell lung cancer (NSCLC) in a subject and methods of stratifying and treating a tumor patient, comprising determining the type of tumor of the patient, and electing patients diagnosed with NSCLC for treatment with the bispecific antibody construct.

The invention relates to a bispecific antibody construct, a taxane, and/or an immune checkpoint inhibitor for use in a method of treating a tumor in a subject, wherein the bispecific antibody construct comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR, wherein the method comprises administering to the subject the bispecific antibody construct, the taxane, and the immune checkpoint inhibitor. The invention further relates to a composition comprising a taxane and a bispecific antibody construct that comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR.

The present invention relates to a bispecific antibody construct and/or a VEGFR-2 inhibitor and/or an immune checkpoint inhibitor for use in a method of treating a tumor in a subject, wherein the bispecific antibody construct comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR, wherein the method comprises administering to the subject the bispecific antibody construct, the VEGFR-2 inhibitor, and the immune checkpoint inhibitor. The invention further relates to corresponding (pharmaceutical) compositions and combination comprising the bispecific antibody construct and/or a VEGFR-2 inhibitor and/or an immune checkpoint inhibitor.

An intelligent defibrillator operating system through movement detection according to an exemplary embodiment of the present disclosure may include a power supply unit for supplying power to an automated external defibrillator (AED); a display unit provided with a display configured to output a warning notification to guide a user of the AED regarding a usage method of the AED, a defibrillation procedure using the AED, and a necessity of an electric shock based on a defibrillation pulse to a patient; and a voice output unit provided with a speaker; an electrode attached to a part of the patient's body to receive an ECG (electrocardiogram) signal of the patient; a defibrillation pulse unit configured to receive the ECG signal of the patient through the electrode; a sensing unit configured to detect a tilt variation (Δθ), a tilt holding time, an acceleration variation (Δa), a tilt value (0), and holding times of the tilt and acceleration of the AED; and a control unit configured to analyze the ECG signal of the patient received by the defibrillation pulse unit, and to control an operation of the AED based on the tilt, the acceleration, and the holding times of variations in the tilt and the acceleration of the AED.

A guidance device through detection of cardiopulmonary resuscitation (CPR) performance includes a pair of electrode pads configured to be attached to a patient's body; a signal providing unit configured to provide a signal to the pair of electrode pads; a differential amplifier connected to the pair of electrode pads and configured to generate an amplified signal proportional to a difference between input signals at both ends provided from the signal providing unit; and a control unit configured to store a normal speed range for a plurality of amplified signals generated from the differential amplifier, and determine whether CPR is being performed and whether CPR is performed normally based on a speed of the plurality of amplified signals generated from the differential amplifier.

The present invention relates to a novel TCR characterized by its CDR3 sequences of the α chain variable region and/or the β chain variable region. The present invention relates to a TCR polypeptide complex and/or a combination comprising a novel TCR characterized by its CDR3 sequences of the α chain variable region and/or the β chain variable region. The present invention further relates to a nucleic acid, a vector as well as a host cell comprising said nucleic acid or said vector. The present invention relates to a method for obtaining said TCR and said chimeric co-stimulatory receptor and to a pharmaceutical or diagnostic composition comprising the abovementioned. The present invention further relates to the abovementioned for use as a medicament or for use in a method of diagnosing, detecting, preventing, and/or treating cancer. Furthermore, the present invention relates to a method of detecting the presence of a cancer in a subject in vitro, by applying within said method the abovementioned, and the use of the abovementioned for generating modified lymphocytes and a kit.